Get the Stockscreener App
1.26
3.08%
-0.04
Pre-market:
1.30
0.04
+3.17%
Neurosense Therapeutics Ltd stock is traded at $1.26, with a volume of 143.51K.
It is down -3.08% in the last 24 hours and down -40.00% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.30
Open:
$1.3
24h Volume:
143.51K
Relative Volume:
0.42
Market Cap:
$32.97M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-1.3548
EPS:
-0.93
Net Cash Flow:
-
1W Performance:
+16.67%
1M Performance:
-40.00%
6M Performance:
+8.62%
1Y Performance:
+100.64%
1-Day Range:
$1.22
$1.3299
1-Week Range:
$1.06
$1.52
52-Week Range:
$0.6355
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.26 | 32.97M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Should you hold or exit NeuroSense Therapeutics Ltd. nowReal-Time Investment Picks with Accuracy - Newser
Why NeuroSense Therapeutics Ltd. is moving todayFree Stock Screener With Smart Filters - Newser
Applying chart zones and confluence areas to NeuroSense Therapeutics Ltd. Equity WarrantFree Secure Return Focused Investment Plan - Newser
What institutional flow reveals about NeuroSense Therapeutics Ltd. Equity WarrantFree Community Verified Stock Suggestions - Newser
What indicators show strength in NeuroSense Therapeutics Ltd.Fundamental Forecast for Undervalued Stocks - Newser
Chart based exit strategy for NeuroSense Therapeutics Ltd.Weekly Outlook for Short Term Investors - Newser
Detecting price anomalies in NeuroSense Therapeutics Ltd. Equity Warrant with AIAlgorithmic Prediction of Market Breakouts - Newser
How hedge fund analytics apply to NeuroSense Therapeutics Ltd. stockSmart Money Strategy for Growth Stocks - Newser
NeuroSense Therapeutics Ltd. Equity Warrant Company Revenue and Profit Trends: A Deep DiveSecure Entry Point Finder with Analysis - Newser
Published on: 2025-08-08 18:28:49 - Newser
Can NeuroSense Therapeutics Ltd. Equity Warrant hit a new high this monthEarnings Based Stock Performance Forecast - Newser
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionFree Investment Strategy With Low Risk - Newser
Maxim Group Analyst Maintains Hold Rating on Neurosense Therapeutics Ltd. - AInvest
What Fibonacci levels say about NeuroSense Therapeutics Ltd. reboundReal-Time AI Generated Market Forecast - Newser
Should you wait for a breakout in NeuroSense Therapeutics Ltd.Early Buy Opportunity with Chart Triggers - Newser
What is NeuroSense Therapeutics Ltd. company’s growth strategyAchieve breakthrough investment performance - Jammu Links News
What are analysts’ price targets for NeuroSense Therapeutics Ltd. in the next 12 monthsInvest confidently with professional market insights - Jammu Links News
What institutional investors are buying NeuroSense Therapeutics Ltd. Equity Warrant stockAchieve breakthrough growth with proven strategies - Jammu Links News
What institutional investors are buying NeuroSense Therapeutics Ltd. stockDynamic growth stocks - Jammu Links News
How volatile is NeuroSense Therapeutics Ltd. stock compared to the marketConsistent wealth multiplication - Jammu Links News
How strong is NeuroSense Therapeutics Ltd. company’s balance sheetFree Consultation - Jammu Links News
What are NeuroSense Therapeutics Ltd. company’s key revenue driversAccelerate your capital gains today - Jammu Links News
How does NeuroSense Therapeutics Ltd. Equity Warrant generate profit in a changing economyBreakthrough stock performance - Jammu Links News
What are the technical indicators suggesting about NeuroSense Therapeutics Ltd. Equity WarrantConsistently profitable trades - Jammu Links News
What analysts say about NeuroSense Therapeutics Ltd. stockInvest confidently with actionable market data - Jammu Links News
NeuroSense Therapeutics Ltd. Equity Warrant Stock Analysis and ForecastTremendous financial leverage - Jammu Links News
What are the latest earnings results for NeuroSense Therapeutics Ltd. Equity WarrantDynamic portfolio growth - Jammu Links News
How does NeuroSense Therapeutics Ltd. Equity Warrant compare to its industry peersBreakthrough profit margins - Jammu Links News
When is NeuroSense Therapeutics Ltd. Equity Warrant stock expected to show significant growthAchieve fast wealth growth with smart picks - Jammu Links News
NeuroSense Therapeutics Ltd. Stock Analysis and ForecastNavigate market volatility with smart strategies - Jammu Links News
How does NeuroSense Therapeutics Ltd. compare to its industry peersBuild wealth faster with disciplined trading - Jammu Links News
How volatile is NeuroSense Therapeutics Ltd. Equity Warrant stock compared to the marketBuild a diversified portfolio for risk management - Jammu Links News
What is NeuroSense Therapeutics Ltd. Equity Warrant company’s growth strategyGet exclusive market analysis for investors - Jammu Links News
Is NeuroSense Therapeutics Ltd. a good long term investmentBreakthrough capital growth - Jammu Links News
Published on: 2025-08-03 03:33:27 - Jammu Links News
What makes NeuroSense Therapeutics Ltd. Equity Warrant stock price move sharplyGrow your wealth with proven stock picks - Jammu Links News
How many analysts rate NeuroSense Therapeutics Ltd. Equity Warrant as a “Buy”Stay ahead with daily expert stock picks - Jammu Links News
Volume Surge May Signal Institutional Interest in NeuroSense Therapeutics Ltd. Equity WarrantWeekly Stock Watch With Growth Focus Expanded - beatles.ru
Is NeuroSense Therapeutics Ltd. a growth stock or a value stockFree Stock Target Finder With Proven Results - Jammu Links News
NeuroSense Therapeutics: Navigating the ALS Treatment Frontier Amid Financial Constraints - AInvest
Neurosense Therapeutics shares rise 5.56% after-hours following a positive business update and progress report. - AInvest
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
NeuroSense Therapeutics Advances ALS Treatment with Phase 3 Trial Plans - TipRanks
Sector Rotation Brings NeuroSense Therapeutics Ltd. Into FocusVerified Signal From Chart Patterns Detected - metal.it
NeuroSense's ALS Drug Achieves Breakthrough: 40% Slower Decline, 74% Better Survival as Phase 3 Nears - Stock Titan
Does NeuroSense Therapeutics Ltd. stock perform well during market downturnsExpert Picks Signals To Watch Now - Jammu Links News
NeuroSense Therapeutics Ltd. Equity Warrant stock prediction for this weekEntry Zone Strategy for Consistent Profit Shared - metal.it
What is the risk reward ratio of investing in NeuroSense Therapeutics Ltd. Equity Warrant stockPre Market Forecasts That Work - Jammu Links News
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):